Heart attack(myocardialinfarction) is a medical emergency in pregnancy which can be fatal to pregnant woman and fetus if left untreated. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of the drug on the fetus. In animal reprod...
Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y₁₂ inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y₁₂ inhibitors are used clinically as effective inhibitors of aden
Tirofiban, another intravenous antiplatelet drug which belongs to the class of Glycoprotein IIb/IIIa inhibitors (GPIs), yielded superior inhibition of platelet aggregation (IPA) over cangrelor at 30 min after infusion. However, cangrelor and tirofiban were both superior to chewed prasugrel [41]....
Tirofiban, another intravenous antiplatelet drug which belongs to the class of Glycoprotein IIb/IIIa inhibitors (GPIs), yielded superior inhibition of platelet aggregation (IPA) over cangrelor at 30 min after infusion. However, cangrelor and tirofiban were both superior to chewed prasugrel [41]....